All In Biotech

NDA 021660 · Bristol-Myers

Abraxane

Paclitaxel · Intravenous · Microtubule Inhibitor

Orphan

Last checked: Nov 20, 2026Latest source record: Aug 25, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Jan 7, 2005

Approved uses

5

Original approval plus efficacy supplements

Registered trials

5,298

1,055 Phase 3, 888 recruiting

FAERS reports

101,114

97,345 serious, 16,524 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE MYELOSUPPRESSION • Do not administer ABRAXANE therapy to patients with baseline neutrophil counts of less than 1,500 cells/mm 3 [see Contraindications (4) ]. • Monitor for neutropenia, which may be severe and result in infection or sepsis [see Warnings and Precautions (5.1 , 5.3) ]. • Perform frequent complete blood cell counts on all patients receiving ABRAXANE [see Warnings and Precautions (5.1 , 5.3) ]. WARNING: SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning . • Do not administer ABRAXANE therapy to patients with baseline neutrophil counts of less than 1,500 cells/mm 3 . ( 4 ) • Monitor for neutropenia, which may be severe and result in infection or sepsis. ( 5.1 , 5.3 ) • Perform frequent complete blood cell counts on all patients receiving ABRAXANE. ( 5.1 , 5.3 )

What it is approved for

From the label in effect Oct 31, 2022.

ABRAXANE is a microtubule inhibitor indicated for the treatment of: • Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. ( 1.1 ) • Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ( 1.2 ) • Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. ( 1.3 ) 1.1 Metastatic Breast Cancer ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. 1.2 Non-Small Cell Lung Cancer ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. 1.3 Adenocarcinoma of the Pancreas ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.

Mechanism: ABRAXANE is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ABRAXANE · PACLITAXEL 100MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Paclitaxel" as an intervention, any sponsor and status, largest first.

All 5,298 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea5,613
  • neutropenia5,563
  • off label use5,388
  • diarrhoea5,265
  • dyspnoea5,190
  • anaemia4,891
  • death4,509
  • malignant neoplasm progression4,508
  • fatigue4,309
  • neuropathy peripheral4,095
  • pyrexia3,984
  • disease progression3,938

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004626
2005853
2006665
2007687
2008946
20091,096
20101,148
20111,956
20122,607
20132,742
20142,623
20153,931
20164,464
20174,527
20186,481
20196,495
20206,372
20216,872
20228,471
20238,823
202410,274
202510,694
20267,760

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Abraxane (Paclitaxel Protein-Bound)

2024 spending

$7.2M

Beneficiaries

234

984 claims

Per beneficiary

$30,613

$1,528.03 per unit

View as table
YearSpending
2020$9,792,937
2021$9,534,885
2022$6,230,058
2023$7,462,298
2024$7,163,424

Part B: Abraxane* (Paclitaxel Protein-Bound*) · HCPCS J9264

2024 spending

$263M

Beneficiaries

13,324

82,225 claims

Per beneficiary

$19,747

2024 ASP limit $13.65 per unit

View as table
YearSpending
2020$339,499,319
2021$333,905,537
2022$324,160,700
2023$283,940,703
2024$263,102,491

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,218 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.